Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib;   Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor:   Henan Cancer Hospital Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials